Overview on proteins as biomarkers in liquid biopsy for MPM
| Author | Biomarker | Study design | Samples | Role |
|---|---|---|---|---|
| Robinson et al. 2013 [16] | SMRP | MPM = 44; HS = 68 (40 AES); OPD = 160 | Serum | Diagnosis: MPM vs. OPD(sensitivity 84%, specificity 100%) |
| Creaney et al. 2011 [24] | SMRP | MPM = 97 | Serum | Prognosis; response to treatment |
| Wheatley-Price et al. 2010 [25] | SMRP | MPM = 41 | Plasma | Response to treatment |
| Pass et al. 2005 [34] | OPN | MPM = 76; AES = 69 | Serum | Diagnosis: MPM vs. AES(sensitivity 77.6%, specificity 85.5%) |
| Cristaudo et al. 2011 [39] | SMRP + OPN | MPM = 31; BRD = 204 | Serum; plasma | Diagnosis: MPM vs. BRD(sensitivity 80%, specificity 91.2%) |
| Pass et al. 2012 [42] | FBLN3 | MPM = 92; AES = 136; OPE = 93; HS = 43 | Plasma | Diagnosis: MPM vs. AES(sensitivity 100%, specificity 94.1%) |
| MPM = 74; OPE = 93 | Pleural effusion | Diagnosis: MPM vs. OPE(sensitivity 83.8%, specificity 92.4%) | ||
| Creaney et al. 2014 [43] | FBLN3 | MPM = 82; OPE = 71 | Pleural effusion | Diagnosis: MPM vs. OPE (sensitivity 22%, specificity 95%); prognosis |
| Tabata et al. 2013 [47] | HMGB1 | MPM = 61; AES = 45 | Serum | Diagnosis: MPM vs. AES(sensitivity 34.4%, specificity 100%); prognosis |
| Hirayama et al. 2011 [52] | VEGF | MPM = 46; OPE = 45 | Pleural effusion | Diagnosis: MPM vs. OPE (sensitivity 71.7%, specificity 76%); prognosis |
| Mundt et al. 2014 [59] | CD138 | MPM = 89; OPE = 167 | Pleural effusion | Diagnosis: MPM vs. OPE(sensitivity 74.9%, specificity 61.3%); prognosis |
SMRP: soluble mesothelin related peptide; VEGF: vascular endothelial growth factor; AES: asbestos exposed subject; BRD: benign respiratory diseases; OPD: other pleural diseases; OPE: other pleural effusions
